Trial · NCT06718686
Rifaximin SSD in Dementia Trial
NCT06718686, Phase 1, Phase 2, Recruiting, Jasmohan Bajaj
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rifaximin SSD in Dementia Trial. Trials, record NCT06718686. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06718686
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rifaximin SSD in Dementia Trial
- NCT number
- NCT06718686
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Jasmohan Bajaj
- Conditions
- Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease
- Interventions
- Rifaximin SSD 40 mg IR tablet, Placebo
- First posted
- 2024-12-05
- Last updated
- 2026-04-03
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in stool and serum short-chain fatty acid levels | 10 weeks | Change in SCFA in stool and serum in rifaximin SSD phase vs placebo phase |
| Primary | Change in bile acids in stool and serum | 10 weeks | Change in bile acids in stool and serum in rifaximin SSD phase vs placebo phase |
| Secondary | Systemic inflammatory change | 10 weeks | serum lipopolysaccharide-binding protein (LBP), inflammatory cytokines (IL-6, TNF-α, IL-10, IL-1β) in placebo phase vs Rifaximin SSD phase |
| Secondary | Stool microbiome composition | 10 weeks | 16SrRNA microbiome composition and diversity change in placebo vs Rifaximin SSD phase |
| Secondary | Change in dementia biomarkers | 10 weeks | Plasma concentrations of Aβ42 and Aβ40 to calculate amyloid-β (Aβ)42/40 ratio and plasma concentration of phospho-tau (p-tau)181 in placebo vs Rifaximin SSD phase |
| Secondary | MMSE | 10 weeks | Change in MMSE between the 2 phases |
| Secondary | Cognitive testing using Psychometric Hepatic Encephalopathy Score | 10 weeks | Change in PHES in placebo vs rifaximin SSD phase |
| Secondary | Clinical Dementia Rating - Sum of Boxes (CDR-SB) | 10 weeks | Change in CDR-SB in placebo vs Rifaximin SSD phase |
| Secondary | EncephalApp Stroop performance | 10 weeks | Change in off time and on time in seconds between placebo and rifaximin SSD phases |
| Secondary | Critical flicker fusion analysis | 10 weeks | change in threshold to see CFF fusion in rifaximin SSD vs placebo phases |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06718686
GET https://conductscience.org/api/trials/v1/NCT06718686/registered